To our knowledge, this study is the first cost‐effectiveness analysis comparing the PEM + TRAS + Chemo regimen with the TRAS + Chemo regimen as a first‐line treatment for HER2‐positive gastric or GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.